Skip to content

Radial Immunodiffusion Plates

by Biocell Laboratories, Inc.

510(k) K830911

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK830911 Date10 Jun 1983ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
DDG
Device Class
Class II
Regulation
21 CFR Part 866.5880
Advisory Committee
Immunology
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 1 Oct 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Radial Immunodiffusion Plates are diagnostic devices classified under radial immunodiffusion, a technique used to quantitatively measure antigen concentrations. These plates consist of a plastic base with agar gel containing specific antiserum, enabling precise detection and quantification of antigens such as transferrin, antigen, or control substances through immunoprecipitation patterns.

These plates are intended for laboratory use in immunology settings and are supplied as single-use items. They require no sterilization beyond manufacturer-provided packaging and are regulated under FDA 510(k) clearance (K830911) with a decision date of June 10, 1983. The device falls under product code DDG and is categorized under 21 CFR 866.5880, adhering to traditional review standards for immunology-related diagnostics.

Other devices from Biocell Laboratories, Inc.

Questions

AI-generated answers, 1 Oct 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What is the Radial Immunodiffusion Plate used for in a clinical setting?

    The Radial Immunodiffusion Plate is designed for quantitative measurement of antigen concentrations in immunology laboratories. It uses a plastic base with agar gel containing specific antiserum to detect and quantify antigens such as transferrin or control substances through immunoprecipitation patterns. This method provides precise, reproducible results for diagnostic purposes.

  • Are these plates single-use or reusable?

    These plates are intended for single-use only. They are supplied in sterile packaging by the manufacturer, eliminating the need for additional sterilization procedures. This ensures consistency and reliability in test results while maintaining safety standards.

  • What types of antigens can be measured using these plates?

    The plates are specifically designed to measure antigens such as transferrin, along with other antigens and control substances. The agar gel contains antiserum tailored to bind with these specific targets, enabling accurate quantification through immunoprecipitation.

  • How should these plates be stored before use?

    The plates should be stored according to the manufacturer’s instructions provided in the packaging. Typically, they are kept in a cool, dry place, protected from direct sunlight and extreme temperatures. Since they are single-use and pre-sterilized, proper storage ensures the integrity of the agar gel and antiserum until use.

  • What regulatory pathway does this device follow?

    The Radial Immunodiffusion Plates are regulated under the FDA’s 510(k) clearance process, specifically under product code DDG and categorized under 21 CFR 866.5880. They were granted clearance as substantially equivalent to a predicate device through a traditional review by the Immunology (IM) Advisory Committee, with a decision date of June 10, 1983.